Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, has scheduled its Q4 and Full Year 2024 financial results and business updates announcement for Thursday, March 20, 2025, before US markets open.
The company will host a live webcast at 8:00 a.m. EDT on the same day. Investors can access the press release through Adaptimmune's corporate website's investor section and join the webcast at https://www.gowebcasting.com/13966. Call-in options are available at 1-833-821-0158 (US/Canada) or 1-647-846-2266 (International), with participants advised to dial in 5-10 minutes before the scheduled start.
Adaptimmune Therapeutics (NASDAQ: ADAP), un'azienda di terapia cellulare focalizzata sui tumori solidi, ha programmato l'annuncio dei risultati finanziari del Q4 e dell'Anno Completo 2024 e aggiornamenti aziendali per gioved矛 20 marzo 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiter脿 un webcast dal vivo alle 8:00 a.m. EDT lo stesso giorno. Gli investitori possono accedere al comunicato stampa attraverso la sezione investitori del sito web aziendale di Adaptimmune e partecipare al webcast su https://www.gowebcasting.com/13966. Sono disponibili opzioni di chiamata al 1-833-821-0158 (US/Canada) o 1-647-846-2266 (Internazionale), con i partecipanti che sono invitati a chiamare 5-10 minuti prima dell'inizio programmato.
Adaptimmune Therapeutics (NASDAQ: ADAP), una empresa de terapia celular centrada en los c谩nceres de tumores s贸lidos, ha programado el anuncio de sus resultados financieros del Q4 y del A帽o Completo 2024 y actualizaciones empresariales para el jueves 20 de marzo de 2025, antes de la apertura de los mercados en EE. UU.
La empresa llevar谩 a cabo una transmisi贸n en vivo a las 8:00 a.m. EDT el mismo d铆a. Los inversores pueden acceder al comunicado de prensa a trav茅s de la secci贸n de inversores en el sitio web corporativo de Adaptimmune y unirse a la transmisi贸n en https://www.gowebcasting.com/13966. Las opciones de llamada est谩n disponibles al 1-833-821-0158 (EE. UU./Canad谩) o 1-647-846-2266 (Internacional), aconsejando a los participantes que llamen de 5 a 10 minutos antes del inicio programado.
Adaptimmune Therapeutics (NASDAQ: ADAP), 瓿犿槙 膦呾枒 鞎旍棎 欷戩爯鞚� 霊� 靹疙彫 旃橂 須岇偓電� 2024雲� 4攵勱赴 氚� 鞐瓣皠 鞛 瓴瓣臣 氚� 牍勳雼堨姢 鞐呺嵃鞚错姼 氚滍憸毳� 2025雲� 3鞗� 20鞚� 氇╈殧鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝勳棎 鞓堨爼頄堨姷雼堧嫟.
須岇偓電� 臧欖潃 雮� 鞓れ爠 8鞁� EDT鞐� 霛检澊敫� 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲姅 Adaptimmune鞚� 旮办梾 鞗轨偓鞚错姼 韴瀽鞛� 靹轨厴鞚� 韱淀暣 氤措弰 鞛愲鞐� 鞝戧芳頃橁碃 https://www.gowebcasting.com/13966鞐愳劀 鞗轨簮鞀ろ姼鞐� 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 鞝勴檾 鞐瓣舶 鞓奠厴鞚� 1-833-821-0158 (氙戈淡/旌愲倶雼�) 霕愲姅 1-647-846-2266 (甑牅)鞐愳劀 鞝滉车霅橂┌, 彀戈皜鞛愲姅 鞓堨爼霅� 鞁滌瀾 5-10攵� 鞝勳棎 鞝勴檾頃� 瓴冹潉 甓岇灔頃╇媹雼�.
Adaptimmune Therapeutics (NASDAQ: ADAP), une entreprise de th茅rapie cellulaire ax茅e sur les cancers des tumeurs solides, a pr茅vu l'annonce de ses r茅sultats financiers pour le Q4 et l'Ann茅e Compl猫te 2024 ainsi que des mises 脿 jour commerciales pour jeudi 20 mars 2025, avant l'ouverture des march茅s am茅ricains.
L'entreprise organisera un webcast en direct 脿 8h00 EDT le m锚me jour. Les investisseurs peuvent acc茅der au communiqu茅 de presse via la section investisseurs du site web de l'entreprise Adaptimmune et rejoindre le webcast 脿 l'adresse https://www.gowebcasting.com/13966. Des options de connexion t茅l茅phonique sont disponibles au 1-833-821-0158 (脡tats-Unis/Canada) ou 1-647-846-2266 (International), avec des participants invit茅s 脿 appeler 5 脿 10 minutes avant le d茅but pr茅vu.
Adaptimmune Therapeutics (NASDAQ: ADAP), ein Unternehmen f眉r Zelltherapie, das sich auf solide Tumoren konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse f眉r Q4 und das gesamte Jahr 2024 sowie Unternehmensupdates f眉r Donnerstag, den 20. M盲rz 2025, vor der Er枚ffnung der US-M盲rkte angesetzt.
Das Unternehmen wird am selben Tag um 8:00 Uhr EDT eine Live-Webcast veranstalten. Investoren k枚nnen 眉ber den Investorenbereich der Unternehmenswebsite von Adaptimmune auf die Pressemitteilung zugreifen und dem Webcast unter https://www.gowebcasting.com/13966 beitreten. Telefonische Teilnahmeoptionen sind unter 1-833-821-0158 (USA/Kanada) oder 1-647-846-2266 (International) verf眉gbar, wobei die Teilnehmer gebeten werden, 5-10 Minuten vor dem geplanten Beginn anzurufen.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.
The press release will be available in the . A live webcast and replay can be accessed at . Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
[email protected]
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
[email protected]
To view the source version of this press release, please visit
FAQ
When will Adaptimmune (ADAP) release its Q4 and Full Year 2024 earnings?
How can investors join Adaptimmune's (ADAP) Q4 2024 earnings call?
What time is Adaptimmune's (ADAP) Q4 2024 earnings webcast?
Where can investors find Adaptimmune's (ADAP) Q4 2024 earnings press release?
